logo-loader
viewMGC Pharmaceuticals Ltd

MGC Pharmaceuticals granted licence to import wider range of medicinal cannabis product into Australia

The licence allows for the importation of any MGC Pharma Schedule-4 and Schedule-8 medicinal cannabis products into Australia.

MGC Pharmaceuticals Ltd - MGC Pharmaceuticals receives Import Licence by Australian Office of Drug Control
The licence enables MGC Pharma to import a wider range of products from its Mercury Pharma brand

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKTS:MGCLF) has been granted an Import Licence by the Australian Office of Drug Control (ODC) which allows it to import any of its Schedule 4 and Schedule 8 medicinal cannabis products into Australia.

The Import Licence follows the recent granting of an Indent Wholesale Licence by the Western Australian Department of Health.

It provides an opportunity for MXC’s Australian operations to directly import Schedule-4 - prescription only medication and Schedule-8 - controlled drugs, medicinal cannabis product into Australia from its European production facility.

Decreases handling fees

The company believes the granting of this licence ‘significantly’ decreases logistics and handling fees and supports its business model of providing high-quality affordable medicinal cannabis products to patients.

This process, which was previously facilitated by Cannvalate and Health House International, also progresses the company towards becoming a vertically integrated bio-pharma company with global operations.

Shares have been as much as 30% higher in early trade to 2.8 cents.

Licence "very significant"

Co-founder and managing director Roby Zamer said: “The granting of the import licence in Australia is very significant for our Australian operations, with the logistics savings we are able to become more cost-effective and are also able to expand our product offering to our Australian customers.”

MGC Pharma will now bulk import its medicinal cannabis products for storage, distribution and sale across Australia through its commercial channel partners.

Expansion plans

In due course, MXC will expand importation to encompass a wider range of products including products from its Mercury Pharma brand.

The company continues to work with Cannvalate and other commercial partners to distribute its proprietary products across the Australian market at very affordable pricing points.

MGC’s next step is to expand its sales team and clinic access, increasing retail profit margins alongside its distribution channels.

Quick facts: MGC Pharmaceuticals Ltd

Price: 0.0315 AUD

ASX:MXC
Market: ASX
Market Cap: $47.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

on 29/1/20

2 min read